Key Takeaway: Werewolf Therapeutics, Inc. announced its financial results for the second quarter of 2024 and provided a business update. The report was released on August 8, 2024, from their headquarters in Watertown, Massachusetts. Further details regarding the financial performance and business strategies were not included in the provided text.
Price reaction · baseline $1.71 (2024-08-07 close) · hit pre-market · clean, no other HOWL news in the window
day 0 close
+8.2%
day 1
+10.5%
day 3 · peak
+19.9%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
15%
average across 6 past catalysts
Lead asset
WTX-330
Phase 1 · Advanced or Metastatic Solid Tumors
Full Press Release Details
August 8, 2024
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
WATERTOWN, Mass., August 8, 2024 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)